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This monograph is based on the workshop "Linking Environmental
Agents and Autoimmune Diseases" held at the National Institute of
Environmental Health Sciences held 1-3 September 1998. Thework-
shop brought together immunologists, clinicians, epidemiologists,
molecular biologists, and toxicologists to review current knowledge
about environmental links to autoimmune disease and to identify
data gaps and future research needs. (Environmental agents were
defined as xenobiotic chemicals in the environment; viruses and infec-
tious agents were notconsidered in this particularworkshop.)
The impetus for the workshop was the question ofwhether
environmental agents affect the development or progression ofauto-
immune disease. Ifso, the ultimate goal is to understand the role of
environmental agents and the underlying mechanisms through which
these agents act so that the potential risks ofexposure to these agents
can be assessed and reduced. Theworkshop's objectives were to assem-
ble experts from a variety offields and provide a forum where they
could interact; reviewwhat is known about links between environmen-
tal exposures and autoimmune disease; identify and prioritize research
needs; and develop an integrated, multidisciplinary research agenda.
The following critical questions framed theworkshop's program:
a) Is there an increased risk for autoimmune disease as a result of
environmental exposures? Ifso, what is the magnitude ofthat risk?
Most autoimmune diseases are relatively rare and hence risk may
appear to be low when based on a specific disease. The risk would be
greater ifseveral autoimmune diseases were affected by a chemical
exposure, possibly via common mechanisms. For the population at
large, the risk is probably smaller than it is for certain sensitive popu-
lations. For any individual chemical the risk may be small, but if a
number of (possibly structurally similar) chemicals have similar
effects, the magnitude of risk increases. Finally, the dose response,
prevalence, and persistence ofthe chemical(s) in question all affect the
magnitude ofrisk. Information with respect to these issues is needed
to understand the importance ofenvironmental agents in the devel-
opment or expression ofautoimmune disease.
b) What are the underlying mechanisms? Because many
autoimmune diseases involve different organ systems, pathogenesis is
likely to involve multiple mechanisms. There are several potential
targets for chemicals, including the immune system, the affected
organ(s) (particularly with respect to alteration of antigenic
expression), and the neuroendocrine system. Ifcommon mechanisms
can be identified, it maybe possible to group certain diseases or chemi-
cals together. Understanding the underlyingmechanisms(s) also is crit-
ical for developing biomarkers ofeffect that can be used in testing
strategies. It would also be useful to knowwhether there are common
mechanisms across the varied forms ofimmune response (immune
suppression, allergy, and autoimmune disease). Finally, mechanistic
data would help determine structure-activity relationships, which
frequentlyare the firstconsideration in hazard identification.
c) How should we evaluate the role ofenvironmental agents using
animal testing methods? Chemicals that suppress immune responses
may enhance susceptibility to infectious and neoplastic disease, and
inappropriate stimulation ofthe immune system may result in allergic
or autoimmune disease. To date, toxicologists have primarily focused
their research on immune suppression and allergy. So much progress
has been made in the area of immune suppression that the U.S.
Environmental Protection Agency recently drafted and approved test
guidelines to be used in assessing chemicals for immunosuppressive
effects (1). In the area ofallergy there are tests to assess for contact
sensitizers (2), and a number oflaboratories are working on tests for
chemicals that might elicit respiratory hypersensitivity (3). However,
there are no well-validated methods for assessing autoimmunity. The
workshop was to determine the research necessary to either support
the development and recommendation oftest guidelines or provide a
scientific basis for not recommending testing. Development ofa panel
ofassays depends on the identification ofappropriate animal models.
Again the issue ofcommon mechanisms is important because it is not
feasible to have different tests for every type of autoimmune disease.
Ideally, biomarkers need to be identified that are indicative ofrisk of
more than one type ofautoimmune disease and can be assessed in
humans as well as experimental animal models, providing a bridge
between animal research and human effects.
d) How should we evaluate the role ofenvironmental agents using
epidemiologic studies? There are few human studies examining envi-
ronmental exposures and autoimmune disease. Another purpose ofthe
workshop was to help prioritize hypotheses that could be evaluated in
epidemiologic studies and to stimulate development of exposure
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assessment techniques (as well as biologic markers ofexposure or
response) needed forlarge-scale studies.
The National Research Council of the National Academy of
Sciences has defined risk assessment as comprising some or all ofthe
following components: hazard identification, dose response, exposure
assessment, and risk characterization (4). Hazard identification is a
qualitative assessment that addresses the question, "What types of
effects occur as a result ofchemical exposure?" In this case, the ques-
tion would be "Does a chemical have the potential to induce or exac-
erbate autoimmune disease?" Dose response is a quantitative
assessment and broadly interpreted addresses the question, "Under
what conditions does a chemical cause these effects in humans?"
Exposure assessment is an analysis ofthe level ofexposure in the envi-
ronment and the numbers and types ofindividuals that are likely to
be exposed. Finally, all ofthis information is integrated to develop a
riskcharacterization. It is clear from the foregoing that the state ofthe
sciencewith respect to environmental agents and autoimmune disease
is in theearlystages ofhazard identification.
The peer-reviewed papers in this monograph are divided into six
sections on the basis ofworkshop sessions: the first section includes an
introduction to the immunology ofautoimmunity and autoimmune
diseases and articles on the evidence for the role ofenvironmental
agents in the initiation or progression ofautoimmune conditions,
available screening tests, and considerations for risk assessment; the
second section covers several different issues regarding susceptibility
and susceptible populations; the third section focuses on clinical,
experimental animal models, and epidemiologic studies ofsystemic
autoimmune diseases (scleroderma and systemic lupus erythemato-
sus); the fourth section includes some examples ofwhat are consid-
ered more organ-specific diseases (e.g., thyroiditis); the fifth section
contains articles about specific exposures and mechanisms (e.g., hexa-
chlorobenzene, silica); and the final section consists ofthe consensus
ofresearch needs and priorities developed by workshop participants.
This monograph is intended to provide a resource for developing a
research strategy to address potential links between environmental
agents and autoimmune disease, including the important issue ofthe
interaction between genetic, hormonal, and environmental factors
involved in the etiology and progression ofautoimmune diseases.
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